Supportive Cancer Therapy
Overview
Supportive Cancer Therapy is a scientific journal, published since 2003 in English. The journal's country of origin is United States and its primary focus area is oncology.
Details
Details
Abbr.
Support Cancer Ther
Start
2003
End
2007
Frequency
Quarterly
p-ISSN
1543-2912
e-ISSN
1943-3395
Country
United States
Language
English
Specialty
Oncology
Recent Articles
1.
2.
Kottschade L, Loprinzi C, Rao R
Support Cancer Ther
. 2008 Jul;
4(4):251-3.
PMID: 18632525
Chemotherapy-induced peripheral neuropathy (CIPN) is a troubling side effect that can lead to dose reductions and discontinuation of treatment. This can be quite distressing for patients. Current treatments for CIPN...
3.
Hickok J, Roscoe J, Morrow G, Ryan J
Support Cancer Ther
. 2008 Jul;
4(4):247-50.
PMID: 18632524
Despite the widespread use of 5-HT3 receptor antagonist antiemetics such as ondansetron and granistron, up to 70% of patients with cancer receiving highly emetogenic chemotherapy agents experience postchemotherapy nausea and...
4.
Bendaly E, Jordan C, Staehler S, Rushing D
Support Cancer Ther
. 2008 Jul;
4(4):241-6.
PMID: 18632523
Introduction: Neuropathic pain has been reported to affect 40%-50% of patients with cancer. Patients And Methods: Consecutive patients selected from the outpatient/adult patient palliative care clinic of the Roudebush Veterans...
5.
Fortner B, Schwartzberg L, Stepanski E, Houts A
Support Cancer Ther
. 2008 Jul;
4(4):233-40.
PMID: 18632522
Background: FOLFOX (oxaliplatin/leucovorin/5-fluorouracil) and FOLFIRI (irinotecan/leucovorin/5-fluorouracil) with or without bevacizumab have become standard-of-care regimens in first-line treatment of metastatic colorectal cancer. However, there is a paucity of symptom burden information...
6.
Gregory S, Xie J, Szczudlo T, Williams D, Woodman R, Wilhelm F
Support Cancer Ther
. 2008 Jul;
4(4):225-32.
PMID: 18632521
Purpose: This open-label study evaluated the safety and efficacy of epoetin alfa 60,000 U once weekly Initialsly followed by 60,000 U every 2 weeks in anemic patients with cancer receiving...
7.
Barton D, Loprinzi C, Atherton P, Raymond J, Shanafelt T, Hines S, et al.
Support Cancer Ther
. 2008 Jul;
4(4):219-24.
PMID: 18632520
Purpose: Newer antidepressants with serotonergic effects reduce hot flashes significantly better than placebo. This pilot study was designed to test the efficacy of desipramine, an older antidepressant targeting norepinephrine, in...
8.
Saif M, Juneja V, Black G, Thronton J, Johnson M, Diasio R
Support Cancer Ther
. 2008 Jul;
4(4):211-8.
PMID: 18632519
Background: Palmar-plantar erythordysesthesia (PPE) is the most common toxicity of capecitabine. Preclinical studies have shown that radiation therapy (RT) upregulates thymidine phosphorylase (TP), which could in turn increase the efficacy...
9.
Kretzschmar A, Wiege T, Al-Batran S, Hinrichs H, Kindler M, Steck T, et al.
Support Cancer Ther
. 2008 Jul;
4(4):203-10.
PMID: 18632518
Background: Bone metastases might lead to severe bone pain, pathologic fractures, and hypercalcemia. Osteolytic destruction is caused by the activation of osteoclasts by release of tumor-derived stimulating factors. Bisphosphonates are...
10.
Jatoi A
Support Cancer Ther
. 2008 Jul;
4(4):198-202.
PMID: 18632517
Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale...